Skip to main content
SLBTSL Science Holding LimitedSell4.7·$1.53
SellModerate Confidence
Investment thesis

SL Science Holding shows weak fundamental quality (0/9 Piotroski, no moat) and a confirmed falling-knife downtrend (death cross, RSI 39, bearish MACD), and the engine's own asymmetry check models 0% upside even though a resistance-based price target implies 137% upside — a conflict the data does not resolve, keeping the stock flagged for exit.

Thesis pillars

  • Weak Quality No Moat→Stable
  • Confirmed Falling Knife Downtrend↑Improving
  • Upside Estimate Conflict→Stable
  • +1 more pillar — see the Why tab for full reasoning

Full reasoning →

Open full analysis

SL Science Holding Limited (SLBT) Stock Analysis

Recovery setup

SellVALUE-TRAP 2/5ValueQualityShortModerate Confidence

Healthcare · Biotechnology

Sell if holding. Multiple concerning factors at $1.53: V7 low-quality RISK_OFF penalty: -0.5 (Q=4.6); Weak overall score: 4.7/10.

SL Science Holding Limited manufactures cosmetic skin care and scalp care products. The company's products include SL bio's milk-derived exosome essence, SL bio's tangerine-derived extract, and the MilkExo concentrate series. It also offers research services in armed T-cells,... Read more

$1.53+26.8% A.UpsideScore 4.7/10#199 of 257 Biotechnology
QualityF-score5 / 9FCF yield—
Stop $1.42Target $1.94(resistance)A.R:R 0.0:1

Sell if holding. Multiple concerning factors at $1.53: V7 low-quality RISK_OFF penalty: -0.5 (Q=4.6); Weak overall score: 4.7/10. Chart setup: Death cross but MACD improving, RSI 43. Score 4.7/10, moderate confidence.

Passes 7/9 gates (positive momentum, clean insider activity, no SEC red flags, news events none recent, earnings proximity no date, semi cycle peak clear, materials cycle peak clear). Suitability: speculative.

news + 30-day 8-K events · 5-min refresh

Recent developments

updated 2026-10-14

Recent Developments — SL Science Holding Limited

Generated 2026-10-14T11:52:18Z.

Thesis

Rewards
Sector modifier (Healthcare): +0.5
Positive insider activity
Risks
V7 low-quality RISK_OFF penalty: -0.5 (Q=4.6)
Weak overall score: 4.7/10
Weak growth

Key Metrics

P/E (TTM)—
P/E (Fwd)—
Mkt Cap$847M
EV/EBITDA-1.1
Profit Mgn-72.5%
ROE—
Rev Growth-7.6%
Beta—
DividendNone
Rating analysts—

Quality Signals

Piotroski F5/9MoatNarrow

Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.

Show full disclosure ▾

About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.

Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.

Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.

No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.

No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.

Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.

Methodology · Editorial policy & full disclaimer

Rating Breakdown

2 floor-breakers·1 ceiling hit

Revenue shrinking — -7.6% YoY. Growth thesis broken unless recovery story develops.static

Revenue Growth
0.6
Declining revenue: -8%
Low model confidence on this dimension (33%).

Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static

Quality Rank
1.6
Growth Rank
3.4
Value Rank
5.0
GatesA.R:R UPSIDE_EXHAUSTED (upside=0.0%)Death cross (50MA < 200MA)Momentum 5.9>=5.5Insider activity: OKNo SEC red flagsNEWS EVENTS NONE RECENTEARNINGS PROXIMITY NO DATESEMI CYCLE PEAK CLEARMATERIALS CYCLE PEAK CLEARRecoverySuitability: Speculative
RSI
43 · Neutral
↓ 20D MA↓ 50D MA↓ 200D MADEATH CROSSSupport $1.42Resistance $1.98

Price Targets

$1
$2
A.R:R0.0:1

Position Sizing

ConvictionNone
Suggested %0%
Max %0%
RegimeRisk-Off

Analyst Consensus

Analysts0
Consensus—
Avg Target—

Earnings

We could not retrieve earnings history for SLBT.
The company may be recently listed, pre-revenue, or its beat/miss record wasn't available from our source this run. Earnings signals feed the Growth and Catalyst score dimensions — absence here doesn't affect other dimensions.

Verdict History

reverse chrono — latest first
Loading history...
Verdicts are recorded on every nightly pipeline run. Rows capture transitions (verdict flips, score deltas ≥0.3, entry/TP/SL changes). Rows with a ▶ can be expanded to see the change reason. Aggregate cohort performance is tracked in the recommendation ledger.
Frequently Asked Questions
Is SLBT stock a buy right now?

Sell if holding. Multiple concerning factors at $1.53: V7 low-quality RISK_OFF penalty: -0.5 (Q=4.6); Weak overall score: 4.7/10. Chart setup: Death cross but MACD improving, RSI 43. Prior stop was $1.42. Score 4.7/10, moderate confidence.

What is the SLBT stock price target?

Take-profit target: $1.94 (+26.8% upside). Prior stop was $1.42. Stop-loss: $1.42.

What are the risks of investing in SLBT?

V7 low-quality RISK_OFF penalty: -0.5 (Q=4.6); Weak overall score: 4.7/10; Weak growth.

Is SLBT overvalued or undervalued?

SL Science Holding Limited trades at a P/E of N/A (forward N/A). TrendMatrix value score: 5.0/10. Verdict: Sell.

0
What does SL Science Holding Limited do?SL Science Holding Limited manufactures cosmetic skin care and scalp care products. The company's products include SL...

SL Science Holding Limited manufactures cosmetic skin care and scalp care products. The company's products include SL bio's milk-derived exosome essence, SL bio's tangerine-derived extract, and the MilkExo concentrate series. It also offers research services in armed T-cells, gamma delta T- cells, citrus reticulata (tangerine) extract, and milk-derived exosomes. SL Science Holding Limited was formerly known as SL BIO Co., Ltd. and changed its name to SL Science Holding Limited in June 2026. The company is based in Taipei, Taiwan.

Related stocks: CRMD (CorMedix Inc.) · HRMY (Harmony Biosciences Holdings, I) · ZVRA (Zevra Therapeutics, Inc.) · FENC (Fennec Pharmaceuticals Inc.) · AUPH (Aurinia Pharmaceuticals Inc)
Home › Stocks › SLBT

Latest news

Latest News

Benzinga16d ago
Benzinga16d ago
Benzinga34d ago
Benzinga41d ago
Benzinga41d ago
Benzinga41d ago
Benzinga48d agoFda Decision
Benzinga48d agoFda Decision
Benzinga64d agoProduct
Benzinga72d ago
Benzinga89d agoProduct
Benzinga92d ago
Benzinga96d agoFda Decision
Benzinga100d ago
Benzinga100d ago
Benzinga104d ago
Benzinga104d ago
Benzinga105d ago